Whoa, this is huge!
— Andy Biotech (@AndyBiotech) October 11, 2018
Mice with same-sex parents born for first time via gene editinghttps://t.co/raEdHq85q0
And once again male turns out to be the weaker sex ;)https://t.co/YIUyhHlCtH pic.twitter.com/8CWr5Uaf0c
Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS$ARWR $DRNA $ALNY $ABUS $RXII $SLN #siRNA #RNAi @RNAi_papershttps://t.co/EIwqyqeu8t pic.twitter.com/OxHfRKm0HI
— Oligotherapeutics (@OTSociety) October 12, 2018
Very interesting!
— Andy Biotech (@AndyBiotech) October 16, 2018
Instead of a nurse's dirty hands or another patient's sneeze, most common source of hospital-acquired bloodstream infections is actually the patient's own gut #microbiome!https://t.co/YnBarWpVEMhttps://t.co/7LdL8agvzg pic.twitter.com/o6Tyht5Ch5
This NEW report analyses the dramatic progress in the global immuno-oncology (IO) landscape from Sep 2017 to Sep 2018, with a 67% increase in the number of active agents in the global IO pipeline https://t.co/wOBheWMyIx pic.twitter.com/Qq7mZZarul
— Nature Rev Drug Disc (@NatRevDrugDisc) October 19, 2018
VX-445 in Triple Combination Therapy for Cystic Fibrosis https://t.co/2H3eSrPcto
— NEJM (@NEJM) October 19, 2018
VX-659 in Triple Combination for Cystic Fibrosis https://t.co/9aN1a1DqXN
Editorial: Triple CFTR Modulator Therapy for Cystic Fibrosis https://t.co/cOrgnD5xj7 #NACFC pic.twitter.com/kiCsOZRt7C
Two years of maintenance therapy with Lynparza, marketed by $AZN and $MRK, reduced the risk of progression in advanced BRCA-positive ovarian cancer by 70%. https://t.co/DSzDxrshGW pic.twitter.com/FpoD6A3Lnn
— Matthew Herper (@matthewherper) October 21, 2018
Wow, very interesting work from $JNJ!
— Andy Biotech (@AndyBiotech) November 2, 2018
Nasal gene spray inspired by llama antibodies could prevent all types of fluhttps://t.co/PXbSgyhnZThttps://t.co/vH4B61AjH5 pic.twitter.com/ZTFYmFLJ1G